A Clinical Trial Comparing Short-Term Efficacy and Safety of Exubera and Lantus

Pfizer

Status and phase: Completed; Phase 4

Conditions: Diabetes Mellitus, Type 2

Treatments: Drug: Inhaled Human Insulin (Exubera); Drug: Insulin Glargine (Lantus)

Study type: Interventional

Funder types: Industry

Identifiers

NCT00367445

A2171094

Details and patient eligibility

About

To compare short-term efficacy and safety of Exubera vs Lantus in patients with type 2 diabetes mellitus

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diabetes mellitus Type 2

Exclusion criteria

• Severe Asthma, severe COPD
• Smoking

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: None (Open label)